Spotlight on Mobocertinib (TAK-788) in NSCLC with EGFR Exon 20 Insertion Mutations

Ítems similars

• Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non–Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations From a Phase 1/2 Trial
  per: Riely, Gregory J., et al.
  Publicat: (2021)
• Preclinical Characterization of Mobocertinib Highlights the Putative Therapeutic Window of This Novel EGFR Inhibitor to EGFR Exon 20 Insertion Mutations
  per: Vasconcelos, Pedro E.N.S., et al.
  Publicat: (2020)
• Response to Afatinib in a Patient with NSCLC Harboring Novel EGFR Exon 20 Insertion Mutations
  per: Lin L, et al.
  Publicat: (2020-09-01)
• Response to Afatinib in a Patient with NSCLC Harboring Novel EGFR Exon 20 Insertion Mutations
  per: Lin, Ling, et al.
  Publicat: (2020)
• Structural Basis for the Functional Changes by EGFR Exon 20 Insertion Mutations
  per: Tamirat, Mahlet Z., et al.
  Publicat: (2021)